Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,275.00+4.44%ETH$2,409.90+6.50%GOLD$4,123.90+1.25%OIL$87.80-0.36%
Smart Investors Daily
SID Premium
EN

NASDAQ · ENTX

Entera Bio Ltd.

Healthcare · Biotechnology

$3.05

Up+$0.06 (+1.97%)

Updated Nov 5, 2026, 12:25 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
101.79M
P/E ratio
-41.77
Dividend yield
0.00%
52-week range
$0.91 – $4.20
Volume
136.96K
Avg. volume
154.41K

Price performance · ENTX

ENTX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

ENTX closed at $3.05 after 20 trading sessions, up 21.51% for the selected period.

Last close
$3.05
Period change
+21.51%
Period low
$2.49
Period high
$3.20
Daily close
View OHLC price history
ENTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$3.06$3.12$2.99$3.05136.96K
Nov 2, 2026$3.19$3.29$2.99$3.09329.88K
Oct 30, 2026$3.06$3.24$2.95$3.20292.68K
Oct 29, 2026$3.08$3.189$3.01$3.12140.95K
Oct 28, 2026$3.05$3.195$3.005$3.10181.56K
Oct 27, 2026$2.85$3.13$2.81$3.06203.53K
Oct 26, 2026$2.90$2.90$2.80$2.86232.47K
Oct 23, 2026$2.99$3.02$2.86$2.92256.93K
Oct 22, 2026$3.01$3.04$2.9007$3.02629.48K
Oct 21, 2026$3.12$3.20$2.96$3.05784.6K
Oct 20, 2026$2.79$3.26$2.79$3.02791.93K
Oct 19, 2026$2.66$2.97$2.62$2.94953.14K
Oct 16, 2026$2.72$2.75$2.62$2.68572.89K
Oct 15, 2026$2.49$2.82$2.49$2.771.45M
Oct 14, 2026$2.47$2.565$2.46$2.50784.49K
Oct 13, 2026$2.65$2.65$2.435$2.49755.3K
Oct 12, 2026$2.66$2.775$2.639$2.65305.69K
Oct 9, 2026$2.51$2.72$2.505$2.661.58M
Oct 8, 2026$2.48$2.52$2.45$2.50421.03K
Oct 7, 2026$2.52$2.58$2.45$2.51679.48K

Latest ENTX news

The latest Smart Investors Daily articles mentioning ENTX.

Stock researchCompany · Overview

ENTX research

Overview

Company profile and research snapshot.

Company profile

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ENTX recent ratings
DateFirmRatingTarget
Sep 25, 2026GuggenheimBuy—
Sep 22, 2026Cantor FitzgeraldOverweight—
Sep 18, 2026Leerink PartnersOutperform—
Apr 27, 2026HC Wainwright & Co.Buy—
Feb 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia) These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Enter

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By